HL Mando has patented a composition for intravenous injection containing beta-cyclodextrin molecules with hydroxypropyl groups, suitable for treating Niemann-Pick disease Type C. The composition is pharmaceutically acceptable for intravenous administration, with strict limits on endotoxins, propylene glycol, and propylene oxide. GlobalData’s report on HL Mando gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights HL Mando Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on HL Mando, Driving behavior monitoring was a key innovation area identified from patents. HL Mando's grant share as of February 2024 was 83%. Grant share is based on the ratio of number of grants to total number of patents.

Intravenous composition of beta-cyclodextrin molecules for niemann-pick disease treatment

Source: United States Patent and Trademark Office (USPTO). Credit: HL Mando Corp

A recently granted patent (Publication Number: US11918601B2) discloses a composition for intravenous injection that includes a mixture of beta-cyclodextrin molecules substituted with hydroxypropyl groups. The composition is designed for intravenous administration and meets stringent pharmaceutical standards, containing less than 2 Endotoxin Units (EU) of endotoxins per gram, no more than 0.5% propylene glycol, and less than 1 ppm of propylene oxide. Additionally, the composition includes sodium chloride at 0.9% w/v, has a pH range of 6.0-8.0, is sterile filtered, and can be stored at 15-25°C.

Furthermore, the patented composition has specific limitations on the presence of unsubstituted beta-cyclodextrin and various degrees of hydroxypropyl substitution. The mixture must contain less than 3.5% collectively of unsubstituted beta-cyclodextrin, beta-cyclodextrin with one hydroxypropyl group, and beta-cyclodextrin with two hydroxypropyl groups. Additionally, the composition must have an osmolality of about 300 to 450 mOsm/kg, an average degree of substitution of 3 to 7, and a total impurity content of less than or equal to 0.05% as measured by HPLC. With a concentration ranging from 10 mg/mL to 200 mg/mL, this composition is suitable for intravenous administration to patients and can be further formulated with a pharmaceutically acceptable diluent for enhanced efficacy.

To know more about GlobalData’s detailed insights on HL Mando, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.